Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US10906916B2 · kind B2 · utility
3Cited by
76References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 2019 |
| Grant date | Feb 2, 2021 |
| Priority date | — |
| Expiry date | Jul 18, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R5, R5′, X1, X2, n, and m are described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.